Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics' stock has experienced significant events and performance over the past six months, including a 606% gain. In September 2025, the company reported a 91% response rate in its Phase 2 bladder cancer study for NDV-01, followed by positive 9-month follow-up data showing a 92% overall response rate in NMIBC. In January 2026, Relmada announced receiving written feedback from the FDA supporting its registrational development pathway for NDV-01 in bladder cancer, with plans to initiate Phase 3 trials in the first half of 2026. In November 2025, Relmada Therapeutics reported its third-quarter 2025 financial results, with an EPS of -$0.30, beating forecasts, and highlighted significant cost-cutting measures and strong clinical trial results for NDV-01. In November 2025, Relmada Therapeutics announced the pricing of a $100 million underwritten offering of common stock and pre-funded warrants, which is expected to extend its operational runway through 2028. In December 2025, Jefferies initiated coverage of Relmada Therapeutics with a "Buy" recommendation and a price target of $75, citing a pipeline pivot, and Mizuho also upgraded Relmada's stock to "Outperform" in November 2025, raising its price target to $10.00 based on NDV-01's potential.

Information regarding demand seasonality for Relmada Therapeutics, Inc.'s products and services is not readily available in the provided search results. As a clinical-stage biotechnology company, its revenue generation is primarily tied to research and development milestones and potential future product commercialization, rather than seasonal consumer demand.

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) diseases and oncology conditions. The company's pipeline includes NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, currently in Phase 2 clinical trials for non-muscle invasive bladder cancer (NMIBC). Sepranolone, a neurosteroid epimer of allopregnanolone, is Phase 2b-ready for potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. REL-P11, a modified-release formulation of psilocybin, has completed a Phase 1 safety study for the treatment of metabolic disease. REL-1017 (esmethadone), previously the lead program, was a novel NMDA receptor channel blocker in late-stage development as an adjunctive treatment for major depressive disorder (MDD) in adults. Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate in NMIBC. The company plans to initiate Phase 3 trials for NDV-01 in the first half of 2026, with FDA feedback supporting its registrational development pathway for both high-grade and intermediate-risk NMIBC.

Relmada Therapeutics, Inc. operates in the United States and is headquartered in Coral Gables, Florida.

Relmada Therapeutics' brand reputation over the past year appears to be positively influenced by several key developments, including positive feedback from the FDA regarding its bladder cancer therapy trials and promising clinical trial results for its NDV-01 candidate. Analyst firms like Jefferies and Mizuho have initiated or upgraded coverage with "Buy" or "Outperform" ratings and increased price targets, indicating a favorable view from the investment community. The company's strategic transformation and focus on a specialized oncology and neurology pipeline have also been highlighted. There is no readily available information suggesting specific events that have negatively impacted Relmada Therapeutics' reputation in the past year.

Relmada Therapeutics, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. As of January 7, 2026, Relmada Therapeutics has 53 institutional owners holding a total of 8,393,125 shares, representing approximately 4.88% to 6.93% of the company's stock. Approximately 4.05% of the stock is owned by insiders, and approximately 89.02% of the company's stock is owned by public companies and individual investors (retail). Sergio Traversa, the CEO, owns the most shares of Relmada Therapeutics Inc.